REM-422
Sources
company_release, as of 2026-11-07
https://www.remixtx.com/rem422-myb-acc-asco-2026/
Remix Therapeutics release, 05.21.2026 (company release; opened 2026-10-27), ASCO 2026 oral abstract 6009 (doi 10.1200/JCO.2026.44.16_suppl.6009; abstract not opened): REM-422 phase 1 dose escalation, RP2D biomarker-positive cohort ORR 43% (3 of 7), DoR over one year and ongoing, DCR 100%; no dose-limiting toxicities; most common treatment-related events epistaxis, fatigue and anemia, all grade 1 or 2; responses across subtypes and after ADCs; Orphan Drug (ACC and AML) and Fast Track (ACC). Preliminary.
Brief source A12
company_release, as of 2026-11-07
Passage Bio and Remix merger investor call script, SEC Form 425, 06.24.2026 (company statement via StockTitan; opened earlier this run; page footer lists S-4/A amendments dated 09.21.2026 and 10.05.2026): over 50% of the 40 to 50 patient Phase 2 confirmatory cohort enrolled; initial Phase 2 data mid-2027; FDA aligned on RP2D 24 mg, the Tempus biomarker assay and the Phase 2 design; about 60 to 65% of ACC is MYB poison-exon biomarker positive; US incidence over 1,500 per year and prevalence about 13,000 to 16,000; merger close expected Q4 2026. All company statements, forward looking.
Brief source A14
company_release, as of 2026-11-07
Remix Therapeutics release, 10.28.2026 (company release; text read via search record 2026-11-07): updated interim REM-422 results from ARIA (NCT06118086) selected for a late-breaking oral at the 38th EORTC-NCI-AACR Symposium (ENA 2026), 11.18 to 11.20.2026, Barcelona. Trade press (Small Molecule News) gives abstract 5LBA, Plenary Session 3, 11.19.2026 10:00 CET, titled on durable responses and prolonged PFS in biomarker-positive ACC. Results not yet public.
Brief source A32
company_release, as of 2026-11-07
https://doi.org/10.1200/jco.2026.44.16_suppl.6009
REM-422 ASCO 2026 abstract 6009 (J Clin Oncol 44(16_suppl), doi 10.1200/jco.2026.44.16_suppl.6009; abstract text read 2026-11-07 via search record): 69 enrolled, 59 efficacy evaluable (32 biomarker positive, 24 negative, 3 unknown); 15 at the 24 mg RP2D; biomarker positive at 12 mg or more: 21 of 30 (70%) target-lesion reduction, 14 of 30 (47%) at least 20% shrinkage; RP2D: 3 PRs in 7 biomarker-positive patients (abstract says ORR 42%, company release 43%); RP2D treatment-related epistaxis 60%, fatigue 60%, anemia 40%, all grade 1 or 2; cutoff 01.07.2026. Preliminary.
Brief source A33
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT06118086
A Phase 1/2, Multicenter, Open-label Study of REM-422, a MYB mRNA Degrader, in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
ClinicalTrials.gov API v2 record, retrieved 2026-11-07